Use of a bioassay in healthy men to evaluate diuretic-spironolactone combinations.
The plasma potassium responses to 1 week's treatment with metolazone 0.625 mg, 1.25 mg and 2.5 mg in combination with spironolactone 50 mg, and metolazone 2.5 alone were examined in a double-blind, crossover study in twelve healthy subjects. Spironolactone attenuated the hypokalaemia induced by metolazone--addition of spironolactone 50 mg to metolazone 2.5 mg raised plasma potassium by 0.18 mmol/l (P less than 0.025). In the presence of spironolactone, a linear log metolazone dose-plasma potassium response relationship (P less than 0.01) was demonstrated. Spironolactone was unable to compensate fully for metolazone's hypokalaemic effect although in combination with metolazone 0.625 mg and 1.25 mg, plasma potassium concentration was maintained close to pretreatment levels. The human bioassay employed provided conveniently quantitative information which allows the rational development of a fixed dose diuretic-spironolactone combination tablet.
D000328:Adult; D004232:Diuretics / Q000494:pharmacology*; D004311:Double-Blind Method; D004338:Drug Combinations; D006801:Humans; D008297:Male; D008788:Metolazone / Q000494:pharmacology; D011188:Potassium / Q000097:blood; D013148:Spironolactone / Q000494:pharmacology*
D004232:Diuretics; D004338:Drug Combinations; D013148:Spironolactone; D011188:Potassium; D008788:Metolazone